Video

Patient Profile: A 67-Year-Old Man with mCRPC and Asymptomatic Bone Metastases

Author(s):

Andrew J. Armstrong, MD,Matthew Manning, MD

Centering discussion on a patient profile of mCRPC with asymptomatic bone metastases, experts share best approaches to treating and optimizing outcomes for such patients, including supplement recommendations to prevent bone fractures.

Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Louis Crain Garrot, MD
Related Content
Sandy Srinivas, MD
November 21st 2024

Kidney Cancer NCCN Guidelines Receive Major Updates, Prostate Cancer Adds Targeted Agents

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

177Lu-PSMA-I&T in PSMA+ mCRPC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 13th 2024

177Lu-PSMA-I&T Meets rPFS End Point in PSMA+ mCRPC

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Neeraj Agarwal, MD, FASCO, Presidential Endowed Chair of Cancer Research, Huntsman Cancer Institute; professor, medicine, University of Utah
October 31st 2024

Novel Prostate Cancer Treatment Increases Overall Survival Rates for Late-Stage Prostate Cancer Patients

Bradley C. Carthon, MD, PhD
October 30th 2024

Patients Characteristics, Sequencing Considerations Are Vital in Prostate Cancer Management